Cardiovascular implications of HIV-associated dyslipidemic lipodystrophy

被引：14
|
作者：
Sekhar R.V. [1 ]
Jahoor F. [1 ]
Pownall H.J. [1 ]
Ballantyne C.M. [1 ]
Balasubramanyam A. [1 ]
机构：
[1] Division of Endocrinology, Baylor College of Medicine, Houston, TX 77030, One Baylor Plaza
来源：
Current Atherosclerosis Reports | 2004年 / 6卷 / 3期
基金：
美国国家卫生研究院;
关键词：
Insulin Resistance; Cholesteryl Ester Transfer Protein; Lipodystrophy; Postprandial Lipemia; Intramyocellular Lipid;
D O I：
10.1007/s11883-004-0029-2
中图分类号：
学科分类号：
摘要：
The emergence of a new metabolic syndrome in patients with HIV infection, termed "HIV-associated dyslipidemic lipodystrophy" (HADL), is characterized by central fat redistribution, severe dyslipidemia, and insulin resistance and predisposes to an increased risk of cardiovascular disease. The factors promoting the development of cardiovascular disease in this condition are not well understood and may involve contributions from antiretroviral drugs and components of the HIV virus, as well as inflammatory cytokines, leading to accelerated lipolysis, dyslipidemia, lipotoxic insulin resistance, and vascular inflammation. In this article, we review HADL in terms of metabolic, molecular, and cytokine derangements leading to cardiovascular disease. Copyright © 2004 by Current Science Inc.
引用
收藏
页码：173 / 179
页数：6
相关论文
共 50 条
  • [21] HIV-Associated Lipodystrophy: Impact of Antiretroviral Therapy
    Guaraldi, Giovanni
    Stentarelli, Chiara
    Zona, Stefano
    Santoro, Antonella
    DRUGS, 2013, 73 (13) : 1431 - 1450
  • [22] Plastic surgical options for HIV-associated lipodystrophy
    Nelson, L.
    Stewart, K. J.
    JOURNAL OF PLASTIC RECONSTRUCTIVE AND AESTHETIC SURGERY, 2008, 61 (04): : 359 - 365
  • [23] HIV-associated cervicodorsal lipodystrophy: Etiology and management
    Gold, DR
    Annino, DJ
    LARYNGOSCOPE, 2005, 115 (05): : 791 - 795
  • [24] Current perspectives on HIV-associated lipodystrophy syndrome
    Milinkovic, A
    Martinez, E
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2005, 56 (01) : 6 - 9
  • [25] HIV-associated lipodystrophy syndrome: Description and pathogenesis
    Bodasing, N
    Fox, R
    JOURNAL OF INFECTION, 2003, 46 (03) : 149 - 154
  • [26] Role of NEDD 8 in HIV-associated lipodystrophy
    Esposito, Vincenzo
    Manente, Lucrezia
    Perna, Angelica
    Gargiulo, Miriam
    Viglietti, Rosaria
    Sangiovanni, Vincenzo
    Doula, Nectaria
    Liuzzi, Giuseppina
    Baldi, Alfonso
    De Luca, Antonio
    Chirianni, Antonio
    DIFFERENTIATION, 2009, 77 (02) : 148 - 153
  • [27] The Role of Protease Inhibitors in the Pathogenesis of HIV-Associated Lipodystrophy: Cellular Mechanisms and Clinical Implications
    Flint, Oliver P.
    Noor, Mustafa A.
    Hruz, Paul W.
    Hylemon, Phil B.
    Yarasheski, Kevin
    Kotler, Donald P.
    Parker, Rex A.
    Bellamine, Aouatef
    TOXICOLOGIC PATHOLOGY, 2009, 37 (01) : 65 - 77
  • [28] Cardiovagal autonomic dysfunction in relation to HIV-associated lipodystrophy
    Chow, DC
    Wood, R
    Grandinetti, A
    Shikuma, C
    Schatz, I
    Low, P
    HIV CLINICAL TRIALS, 2006, 7 (01): : 16 - 23
  • [29] The impact of HIV-associated lipodystrophy on healthcare utilization and costs
    Huang J.S.
    Becerra K.
    Fernandez S.
    Lee D.
    Mathews W.C.
    AIDS Research and Therapy, 5 (1)
  • [30] Growth hormone and tesamorelin in the management of HIV-associated lipodystrophy
    Bedimo, Roger
    HIV AIDS-RESEARCH AND PALLIATIVE CARE, 2011, 3 : 69 - 79
12345